CHARLES W CALDWELL, MD
Medical Practice at Marcassin Dr, Columbia, MO

5776754, Jul 7, 1998

Apr 19, 1994

8/229959

Charles William Caldwell - Columbia MO

The Curators of the University of Missouri - Columbia MO

C12N 506, C12N 502, A01N 100

4352402

This invention discloses a population of cells which have been preserved in non-frozen hydrated form, and which have been chemically treated in a manner that renders them metabolically inert and free of proteolytic enzyme activity, but without significantly altering the cell surface proteins that are of interest in flow cytometry. The absence of alteration of the surface proteins is indicated by the ability of the surface proteins to bind to monoclonal antibodies that bind to untreated proteins of the same type, with approximately the same affinity as proteins on untreated cells. The preserved cells and their surface antigens are stable for at least a month when stored at 4. degree. C. in buffered saline solution. These cell preparations are useful as quality control (QC) reagents for processes such as calibrating and standardizing flow cytometry equipment, and for use as "unknown" test samples for QC testing programs, or as patient specimens for archival storage and subsequent retrospective analysis.

2009026, Oct 22, 2009

Oct 27, 2006

12/091718

Charles W. Caldwell - Columbia MO, US
Huidong Shi - Martinez GA, US
Farahnaz Rahmatpanah - Newport Beach CA, US
Kristen H. Taylor - Columbia MO, US
Douglas E. Laux - Iowa City IA, US
Deiter J. Duff - Columbia MO, US
Juyuan Guo - Columbia MO, US

Curators of the University of Missouri - Columbia MO

C40B 30/04, C12Q 1/68

506 9, 435 6

Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL/SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and/or patterns” (IMP and/or IEP) and fusion of gene rankings.

5478722, Dec 26, 1995

Feb 17, 1991

7/652095

Charles W. Caldwell - Columbia MO

The Curators of the University of Missouri - Columbia MO

C12N 950, A01N 102, C12Q 100, G01N 3353

435 11

Cells are treated to preserve them in non-frozen hydrated form with minimal alterations to their antigens or nucleic acids. This makes the cells useful as quality control (QC) reagents for processes such as calibrating and standardizing flow cytometry equipment, for use as "unknown" test samples for QC testing programs, and to prepare patient specimens for archival storage. This method includes: (1) treating the cells to inhibit proteolysis, preferably using several protease inhibitors; (2) fixing the cells, either by contacting them with a crosslinking agent such as formalin or paraformaldehyde, or by exposure to microwave radiation, while the cells are being agitated to promote the formation of crosslinking bonds within a single cell while inhibiting the formation of cell clumps; and (3) if the cells are treated with a chemical crosslinking agent, removing the crosslinking agent and contacting the cells with a quenching agent. The cells should be stored in a solution containing protease inhibitors. This method causes little or no detectable alteration of antigenic or DNA histograms.

2013012, May 23, 2013

Nov 5, 2012

13/668916

THE CURATORS OF THE UNIVERSITY OF MISS - Columbia MO, US
Raghuraman Kannan - Columbia MO, US
Kativa K. Katti - Columbia MO, US
Satish Kumar Nune - Lawrence KS, US
Cathy S. Cutler - Columbia MO, US
Charles Caldwell - Columbia MO, US
Ravi Shukla - Columbia MO, US
Nripen Chanda - Columbia MO, US
Ajit Zambre - Columbia MO, US

THE CURATORS OF THE UNIVERSITY OF MISSOURI - Columbia MO

A61K 9/14, A61P 35/00, A61K 49/00, A61K 51/12, A61K 33/24, B82Y 5/00

424 129, 424490, 424496, 424649, 424 91, 977773, 977906

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavanoids-rich plant material that can be obtained from green tea. The EGCg is an an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. In preferred embodiment method of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with EGCg in a buffer, such as deionized water. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of EGCg. The thermodynamically feasible redox couple of AuCl4-EGCg leading to the reduction of AuCl4- by EGCg to form gold nanoparticles. In another embodiment, pre-cooled gold salt and EGCg solutions form multi-layered EGCg coated particles.

2012020, Aug 9, 2012

Jan 27, 2012

13/360649

Michael Xia WANG - Columbia MO, US
Charles W. Caldwell - Columbia MO, US
Kristen H. Taylor - Columbia MO, US
Srilatha Nalluri - Augusta GA, US
Dali Zheng - St. Louis MO, US

C12Q 1/68

435 611

Provided are new and improved methods for detecting circulating tumor cells and tumor cell DNA in patient blood or other biofluid samples. Particular aspects comprise three steps: DNA extraction from patient samples, DNA digestion with multiple selected methylation-sensitive enzymes, and target amplification by a conventional or a real-time PCR with specific probe and/or primers. Also provided are a total of 40 tumor-specific DNA methylation loci as biomarkers having substantial utility and specificity in major types of human malignancies including hematopoietic and solid tumors.